Phaseline

Companies › Avenzo Therapeutics

Avenzo Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVZO-021
CDK2 inhibitor
CDK2Phase 1Advanced Solid Tumor; HR+/HER2- Breast CancerJan 2028
AVZO-023
CDK4 inhibitor
CDK4Phase 1HR+/HER2- Breast CancerAug 2028
AVZO-103–Phase 1Solid Tumor CancerMar 2030
AVZO-1418–Phase 1Solid Tumor CancerJun 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05867251AVZO-021Phase 1Advanced Solid TumorOncologyJan 2028
NCT06998407AVZO-023Phase 1HR+/HER2- Breast CancerOncologyAug 2028
NCT06998407AVZO-021Phase 1HR+/HER2- Breast CancerOncologyAug 2028
NCT07193511AVZO-103Phase 1Solid Tumor CancerOncologyMar 2030
NCT07038343AVZO-1418Phase 1Solid Tumor CancerOncologyJun 2030

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CDK4 (1) CDK2 (1)

Companies with the same targets

Pfizer NiKang Therapeutics Chia Tai Tianqing Pharmaceutical Group AstraZeneca Novartis Pharmacosmos BeOne Medicines Eli Lilly Jiangsu HengRui Medicine Shandong Suncadia Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.